Svas Biosana S p A : Financial Statements at 31 December 2023 approved

PRESS RELEASE

THE SHAREHOLDERS' MEETING OF SVAS BIOSANA S.p.A.

Approves the financial statements for the year ended 31 December 2023

Resolves the distribution of a dividend of € 0.30

Appoints the Board of Directors for 2024-2026

Appoints the Board of Statutory Auditors for 2024-2026

Resolution on the amendment of certain articles of the Articles of Association

Somma Vesuviana (NA) 15 May 2024 - Svas Biosana S.p.A. (the "Group" or "SVAS"), a leading healthcare sector company, operating in the production and distribution of medical devices for public and private healthcare facilities, listed on Euronext Growth Milan - a multilateral trading system organized and managed by Borsa Italiana S.p.A. dedicated to small and medium-sized enterprises with high growth potential - announces that the Shareholders' Meeting, which met today in first call in compliance with the provisions of Decree-Law no. 18/2020 and subsequent amendments - i.e. without its shareholders being in attendance in person, in an ordinary session, resolved on the financial statements as at 31 December 2023 and on the allocation of the profit for the year, deciding on the distribution of a dividend of € 0.30 per share. The Shareholders' Meeting also appointed the members of the Board of Directors and the Board of Statutory Auditors for the 2024-2026 financial years.

The Shareholders' Meeting, which then met in an extraordinary session, approved some amendments to the Company's Articles of Association.

ORDINARY SHAREHOLDERS' MEETING

1) Approval of the Financial Statements as at 31 December 2023

The Shareholders' Meeting approved the financial statements of the company Svas Biosana S.p.A. which generated sales revenues from operations of € 55.8 million (+0.7% YoY).

The Production Value is € 61.1 million, an increase of +1.2% compared to 2022. EBITDA is € 5.8 million, down 1.6% on the previous year.

EBIT amounts to € 2.1 million, down 5.5% compared to 2022.

Net Profit is € 1.1 million, up 47.0% on 2022.

The Net Financial Position is negative to the tune of € 23.1 million.

The Shareholders' Meeting also examined the Group's consolidated financial statements for the 2023 financial year.

Revenues from operations as at 31 December 2023 amounted to € 118.3 million (+21.7% YoY).

The Production Value is € 122.3 million (+19.6% YoY).

EBITDA amounted to € 14.2 million, up 19.7% compared to 2022.

EBIT amounts to € 8.6 million, up 36.9% on 2022.

Net Profit is € 5.1 million (+43.5% compared to 2022).

The Net Financial Position is negative to the tune of € 23.8 million.

SVAS BIOSANA S.p.A.	Sede Legale	Corrispondenza	Direzione ed Uffici	Contatti
Registro Imprese di	Via M. Perillo, 34	Casella Postale n.91	Via Trentola, 7	Tel. [phone]
Napoli n.4543/85	80047	80049	80049	Fax [phone]
n. R.E.A. 393065	San Giuseppe Vesuviano (NA)	Somma Vesuviana (NA)	Somma Vesuviana (NA)	www.svas.it
C.F. 04720630633	Italy	Italy	Italy	[e-mail]
P. I.V.A. 01354901215

2) Proposed allocation of Operating Profit and part of available reserves

The Shareholders' Meeting resolved to allocate the profit for the year, €1,118,380, as follows:

• € 55,919 as legal reserve;
• € 1,062,461, as dividends, along with a portion of the Extraordinary Reserve of up to € 541,390, by distributing a gross ordinary dividend of € 0.30 for each qualifying ordinary share in circulation (excluding portfolio treasury shares) at the ex-dividend date.

The Shareholders' Meeting also decided that the dividend payment date will be 29 May 2024, with an ex- dividend date of 27 May 2024 and a record date of 28 May 2024.

1. Appointment of the Board of Directors

The Shareholders' Meeting appointed the new Board of Directors - on the basis of the only list received from 21 Monte Somma S.r.l. - which will be in office for the next three financial years, until the date of the shareholders' meeting called to approve the financial statements for the year ending 31 December 2026, and established that the Board of Directors will have four members.

Specifically, the Shareholders' Meeting appointed Mr. Filippo Maraniello as Chairman of the Board of Directors, Mr. Umberto Perillo and Mr. Luigi Gatta as Directors, and Mr. Antonio Finocchi Ghersi as Independent Director.

Finally, the Ordinary Shareholders' Meeting also set gross total annual fees of € 260,000.00 (two hundred and sixty thousand) for the Board of Directors, that will be divided among the latter's members as determined by the Board itself, including fees for any directors who are vested with special tasks, including executive duties, pursuant to Article 2389, 1st and 3rd paragraphs, of the Italian Civil Code.

4) Appointment of the Board of Statutory Auditors

The Shareholders' Meeting also appointed the members of the Board of Statutory Auditors - on the basis of the only list received from 21 Monte Somma S.r.l. - who will be in office for the next three financial years, until the date of the shareholders' meeting called to approve the financial statements for the year ending 31 December 2026.

The Board of Statutory Auditors consists of Mr. Nicola Tino, Mr. Enrico Auriemma and Mr. Simone Vitobello as Standing Auditors; and Mr. Ciriaco Roberto Tino and Ms. Anna Camera as Alternate Auditors.

The annual remuneration payable to each standing auditor for the entire term of office was set as € 9,000 (nine thousand) plus VAT and charges as applicable, while the fee payable to the Chairman of the Board of Statutory Auditors will be € 12,000 (twelve thousand), plus VAT and charges as applicable.

EXTRAORDINARY SHAREHOLDERS' MEETING

All the amendments to the Articles of Association proposed to the Shareholders' Meeting today were approved by a majority of votes. It should be noted that, by way of a precautionary consideration by the Chairman of the Shareholders' Meeting, in relation to the last proposal (amending art. 16 of the Articles of Association) which triggers a termination clause, this was deemed to have occurred after a shareholder expressed their intention to withdraw. As such, the resolved amendment of art. 16 did not come into effect.

SVAS BIOSANA S.p.A.	Sede Legale	Corrispondenza	Direzione ed Uffici	Contatti
Registro Imprese di	Via M. Perillo, 34	Casella Postale n.91	Via Trentola, 7	Tel. [phone]
Napoli n.4543/85	80047	80049	80049	Fax [phone]
n. R.E.A. 393065	San Giuseppe Vesuviano (NA)	Somma Vesuviana (NA)	Somma Vesuviana (NA)	www.svas.it
C.F. 04720630633	Italy	Italy	Italy	[e-mail]
P. I.V.A. 01354901215

* * * * * *

The documentation required by the prevailing legislation for today's Shareholders' Meeting accompanied by the minutes of the Meeting (which also includes information on the number of shares represented at the Shareholders' Meeting and the results of the votes) will be made available to the public at the Company's headquarters, and will be available on the Company's website www.svas.itin the Investor Relations/Shareholders' Meeting section, and on the website of the Italian Stock Exchange www.borsaitaliana.it.

* * * * * *

This press release is available at the Italian Stock Exchange, at the Group's registered office, and in the Investor Relations/Releases section of www.svas.it.

For the disclosure of regulated information Svas Biosana uses the eMarket SDIR circuit, which is managed by Teleborsa S.r.l., with headquarters in Piazza di Priscilla 4, 00199 Rome (www.emarketstorage.com).

Svas Biosana produces and distributes medical devices in Italy and abroad. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, SVAS is now an international player with a catalogue including about 16,000 own-brand and third- party products, with 350 employees, a dedicated Research and Development department, 3 production plants in Italy and subsidiaries in Slovenia, Croatia, Serbia and Bosnia and Herzegovina.

Ticker: ISIN Ordinary Shares: IT0005469264 Ticker: ISIN Warrant SVAS BIOSANA 2021-2024: IT0005469157

Contacts:

SVAS Biosana S.p.A.	Euronext Growth Advisor
Andrea Efficace	Banca Profilo
Group CFO and Investor Relations Manager	Milan, Via Cerva 28
+39 081.8995411	+39 02.584081
[e-mail]	[e-mail]
Investor Relations Advisor	Media Relations Advisor
POLYTEMS HIR	POLYTEMS HIR
Bianca FERSINI MASTELLONI - Silvia MARONGIU	Paolo SANTAGOSTINO
06.69923324-066797849	[phone]
[e-mail]	[e-mail]
Specialist
Banca Profilo
+39 02.584081

SVAS BIOSANA S.p.A.	Sede Legale	Corrispondenza	Direzione ed Uffici	Contatti
Registro Imprese di	Via M. Perillo, 34	Casella Postale n.91	Via Trentola, 7	Tel. [phone]
Napoli n.4543/85	80047	80049	80049	Fax [phone]
n. R.E.A. 393065	San Giuseppe Vesuviano (NA)	Somma Vesuviana (NA)	Somma Vesuviana (NA)	www.svas.it
C.F. 04720630633	Italy	Italy	Italy	[e-mail]
P. I.V.A. 01354901215